Pharmacoepidemiological studies: What levels of evidence and how can they be reached?;Études pharmaco-épidémiologiques: quels niveaux de preuve et comment les atteindre ?

Therapie

Volumn 68, Issue 4, 2013, Pages 241-246

  Lapeyre Mestre, Maryse ^a   Sapède, Claudine ^b   Moore, Nicholas ^c   Bilbault, Pascal ^d   Blin, Patrick ^c   Chopy, Damien ^e   Evans, David ^f   Gueyffier, François ^g   Lacoin, Laure ^h   Malbezin, Muriel ⁱ   Micallef, Joëlle ^j   Morlet Vigier, Dana ^k   Muller, Sophie ^l   Oger, Emmanuel ^m   Plétan, Yannick ⁿ   Pons, Gérard ^o   Verpillat, Patrice ^p   Vigneau, Caroline ^q  

^a Faculté de Médecine Centre Hospitalo universitaire   (France)

^b Laboratoire Roche   (France)

^c UNIVERSITÉ DE BORDEAUX   (France)

^d BOEHRINGER INGELHEIM   (France)

^e INSERM   (France)

^f Laboratoires Lilly   (France)

^g UNIVERSITÉ LYON 1   (France)

^h Ancien Délégué Général de la Fédération de l'Hospitalisation Privée   (France)

ⁱ Laboratoire Janssen   (France)

^j TIMONE HOSPITAL   (France)

^k IQVIA   (United States)

^l GLAXOSMITHKLINE   (France)

^m UNIVERSITÉ DE RENNES 1   (France)

ⁿ Laboratoire Roche Pharma   (France)

^o UNIVERSITÉ PARIS DESCARTES   (France)

^p Lundbeck   (France)

^q NANTES UNIVERSITY HOSPITAL   (France)

more..

Author keywords

Effectiveness; valuation; Niveau de preuve; Population rejointe; Risque

Indexed keywords

ARTICLE; PHARMACOEPIDEMIOLOGY; PRIORITY JOURNAL; ANTICOAGULANT THERAPY; BLEEDING; CLINICAL EFFECTIVENESS; DIARRHEA; DRUG EFFICACY; DRUG MARKETING; DRUG MONITORING; DRUG SAFETY; EVIDENCE BASED MEDICINE; HEALTH INSURANCE; HUMAN; NONHUMAN; PATIENT COMPLIANCE; PRACTICE GUIDELINE; PRESCRIPTION; RISK ASSESSMENT; ADVERSE DRUG REACTION; CONFERENCE PAPER; CONSENSUS DEVELOPMENT; EPIDEMIOLOGY; EVIDENCE BASED PRACTICE; METHODOLOGY; PATIENT SAFETY; STANDARD; STATISTICS; TREATMENT OUTCOME; DRUG-RELATED SIDE EFFECTS AND ADVERSE REACTIONS; PROCEDURES; STANDARDS; STATISTICS AND NUMERICAL DATA;

ANTIBIOTIC AGENT; ANTICOAGULANT AGENT; BENZODIAZEPINE DERIVATIVE;

DRUG-RELATED SIDE EFFECTS AND ADVERSE REACTIONS; EPIDEMIOLOGIC RESEARCH DESIGN; EVIDENCE-BASED PRACTICE; HUMANS; PATIENT SAFETY; PHARMACOEPIDEMIOLOGY; TREATMENT OUTCOME;

EID: 84883529778     PISSN: 00405957     EISSN: 19585578     Source Type: Journal    
DOI: 10.2515/therapie/2013037     Document Type: Article

References (18)

1. Le Gales C, Hasnaoui A, Goehrs JM. Postmarketing evaluation of drugs. Actual efficacy, population exposed and impact on public health. Therapie 2003; 58 (3): 209-19
2. Vray M, Hamelin B, Jaillon P. The respective roles of controlled clinical trials and cohort monitoring studies in the pre-and postmarketing assessment of drugs. Therapie 2005; 60 (4): 339-44, 345-9
3. Tubach F, Lamarque-Garnier V, Castot A. Role of the post-marketing authorisation studies in drug risk surveillance: specifications and methodologies. Therapie 2011; 66 (4): 355-62, 347-54
4. Gueyffier F, Strang CB, Berdaux G, et al. Contribution of modeling approaches and virtual populations in transposing the results of clinical trials into real life and in enlightening public health decisions. Therapie 2012; 67 (4): 367-74
5. Hill AB. The environment and disease: association or causation? Proc R Soc Med 1965; 58: 295-300
6. Haute autorité de santé. Élaboration de recommandations de bonne pratique : Méthode Recommandations pour la pratique clinique in Guide méthodologique. 2010. http://www.has-sante.fr/ portail/upload/docs/application/pdf/2011-01/guide-methodologique- recommandations-pour-la-pratique-clinique.pdf
7. Trans Durieux N, Pasleau F, Howick J. Table des niveaux de preuves du Centre d'Evidence?Based Medicine d'Oxford (OCEBM Levels of Evidence Working Group). The Oxford 2011 Levels of Evidence, 2011. http://www.cebm.net
8. Balshem H, Helfand M, Schünemann HJ, et al. GRADE guidelines: 3. Rating the quality of evidence. J Clin Epidemiol 2011; 64 (4): 401-6
9. Howick J, Glasziou P, Aronson JK. The evolution of evidence hierarchies: what can Bradford Hill's 'guidelines for causation' contribute? J R Soc Med 2009; 102 (5): 186-94
10. Howick JP, Glasziou P, Aronson JK. Evidence-based mechanistic reasoning. J R Soc Med 2010; 103 (11): 433-41
11. Wald NJ, Morris JK. Teleoanalysis: combining data from different types of study. BMJ 2003, 327 (7415): 616-8
12. Loke YK, Price D, Herxheimer A. Systematic reviews of adverse effects: framework for a structured approach. BMC Med Res Methodol 2007; 7: 32
13. Singh S, Loke YK, Furberg CD. Thiazolidinediones and heart failure: a teleo-analysis. Diabetes Care 2007; 30 (8): 2148-53
14. Edwards IR, Aronson JK. Adverse drug reactions: definitions, diagnosis, and management. Lancet 2000; 356 (9237): 1255-9
15. Blake KV, Devries CS, Arlett P, et al. Increasing scientific standards, independence and transparency in post-authorisation studies: the role of the European Network of Centres for Pharmacoepidemiology and Pharmacovigilance. Pharmacoepidemiol Drug Saf 2012; 21 (7): 690-6
16. Blake KV, Prilla S, Accadebled S, et al. European Medicines Agency review of post-authorisation studies with implications for the European Network of Centres for Pharmacoepidemiology and Pharmacovigilance. Pharmacoepidemiol Drug Saf 2011; 20 (10): 1021-9
17. Berger ML, Dreyer L, Anderson F, et al. Prospective observational studies to assess comparative effectiveness: the ISPOR good research practices task force report. Value Health 2012; 15 (2): 217-30
18. Stamenkovic S, Solesse A, Zanetti L, et al. French Health Authority (HAS) Guidance: the post-registration studies on health technologies (drugs, medical devices and instruments): principles and methods. Therapie 2012; 67 (5): 409-21